Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.
Mult Scler J Exp Transl Clin
; 10(1): 20552173241233952, 2024.
Article
em En
| MEDLINE
| ID: mdl-38435499
ABSTRACT
Objective:
To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.Methods:
We included 15 consecutive patients, who were started on a treatment of dalfampridine 10â mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.Results:
The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds (p = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) (p = 0.004).Conclusion:
Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Mult Scler J Exp Transl Clin
Ano de publicação:
2024
Tipo de documento:
Article